Anest. intenziv. Med. 2025;36(1):46-51 | DOI: 10.36290/aim.2025.004

Angiotensin II - mechanism of action, current evidence and position paper of the interdisciplinary working group on its use in intensive care settingsNew guidelines

Balík M.1, Beneš J.2, Černý V.3, 4, 5, 6, 7, 8, Kula R.9, Matějovič M.10, Říha H.11, Tencer T.12
1 Klinika anesteziologie, resuscitace a intenzivní medicíny VFN a 1. LF UK, Praha
2 Klinika anesteziologie, resuscitace a intenzivní medicíny, LF v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň
3 Klinika anesteziologie, perioperační a intenzivní medicíny, Masarykova nemocnice v Ústí nad Labem, J. E. Purkyně v Ústí nad Labem
4 Národní institut kvality a excelence zdravotnictví, Praha
5 Klinika anesteziologie a resuscitace, Fakultní nemocnice Královské Vinohrady, Univerzita Karlova v Praze, 3. LF UK, Praha
6 Klinika anesteziologie, resuscitace a intenzivní medicíny, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové
7 Dept. of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada
8 Ústav klinických oborů a biomedicíny, Technická univerzita Liberec
9 Klinika anesteziologie, resuscitace a intenzivní medicíny FN a LF OU, Ostrava
10 I. interní klinika, LF v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň
11 Klinika anesteziologie a resuscitace, Kardiocentrum IKEM, Praha
12 Klinika anesteziologie, resuscitace a intenzivní medicíny 2. LF UK a FN Motol, Praha

The medicinal product Giapreza containing angiotensin II for intravenous administration has been registered in the Czech Republic since 2023. The article describes the mechanism of action of the drug, summarizes the current scientific evidence of its efficacy and safety, and presents the opinion of an interdisciplinary working group on the use of angiotensin II in intensive care units, especially in patients with refractory vasoplegic shock. The text has been endorsed by the Czech Society of Intensive Medicine, the Czech Society of Anesthesiology and Intensive Medicine, and the Czech Acute Cardiac Care Association.

Keywords: angiotensin II, vasoplegia, septic shock, VA­‑ECMO, extracorporeal circuit, angiotensin converting enzyme inhibitor, renin.

Received: February 7, 2025; Revised: February 7, 2025; Accepted: February 11, 2025; Prepublished online: March 17, 2025; Published: April 28, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Balík M, Beneš J, Černý V, Kula R, Matějovič M, Říha H, Tencer T. Angiotensin II - mechanism of action, current evidence and position paper of the interdisciplinary working group on its use in intensive care settings. Anest. intenziv. Med. 2025;36(1):46-51. doi: 10.36290/aim.2025.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 28.4.2026

    References

    1. . Landoni G, Cortegiani A, Bignami E, De Pascale G, Donadello K, Donati A, et al. The use of angiotensin II for the management of distributive shock: expert consensus statements. J Anesth Analg Crit Care. 2024;4(1):56. Go to original source... Go to PubMed...
    2. . SUKL CMEC. decision on Giapreza 19. 1. 2023
    3. . Xourgia E, Exadaktylos AK, Chalkias A, Ziaka M. Angiotensin II in the treatment of distributive shock: a systematic­‑review and meta­‑analysis. Shock. 2024;62(2):155-64.
    4. . Coulson TG, Miles LF, Zarbock A, Burrell LM, Patel SK, von Groote T, et al. Renin­‑angiotensin­‑aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial. British Journal of Anaesthesia. 2023;131(4):664-72. Go to original source... Go to PubMed...
    5. . Sadjadi M, von Groote T, Weiss R, Strauß C, Wempe C, Albert F, et al. A Pilot Study of Renin­‑Guided Angiotensin­‑II Infusion to Reduce Kidney Stress After Cardiac Surgery. Anesthesia & Analgesia. 2024;139(1):165-73. Go to original source... Go to PubMed...
    6. . Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017;377(5):419-30. Go to original source... Go to PubMed...
    7. . Bellomo R, Zarbock A, Landoni G. Angiotensin II. Intensive Care Med. 2024;50(2):279-82. Go to original source... Go to PubMed...
    8. . Leisman DE, Privratsky JR, Lehman JR, Abraham MN, Yaipan OY, Brewer MR, et al. Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model. Proc Natl Acad Sci U S A. 2022;119(34):e2211370119. Go to original source... Go to PubMed...
    9. . Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, et al. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post­‑hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023;27(1):175. Go to original source... Go to PubMed...
    10. . Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, et al. Angiotensin II for the Treatment of High­‑Output Shock 3 (ATHOS-3): protocol for a phase III, double­‑blind, randomised controlled trial. Crit Care Resusc. 2017;19(1):43-9. Go to original source...
    11. . Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, et al. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med. 2018;46(6):949-57. Go to original source... Go to PubMed...
    12. . Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and Survival in Patients Given Angiotensin II for Catecholamine­‑Resistant Vasodilatory Shock. A Clinical Trial. Am J Respir Crit Care Med. 2020;202(9):1253-61. Go to original source... Go to PubMed...
    13. . Chappell MC, Schaich CL, Busse LW, Martin GS, Sevransky JE, Hinson JK, et al. Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post­‑hoc analysis from the VICTAS trial. Crit Care. 2024;28(1):333. Go to original source... Go to PubMed...
    14. . Eleuteri D, Montini L, Cutuli SL, Rossi C, Alcaro F, Antonelli M. Renin­‑angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report. Crit Care. 2021;25(1):91. Go to original source... Go to PubMed...
    15. . Heinicke U, Adam E, Sonntagbauer M, von Knethen A, Zacharowski K, Neb H. Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single­‑center experience. Crit Care. 2020;24(1):409. Go to original source... Go to PubMed...
    16. . Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med. 2017;45(8):1285-94. Go to original source... Go to PubMed...
    17. . Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, et al. NOREPINEPHRINE: NOT TOO MUCH, TOO LONG. Shock. 2015;44(4):305-9. Go to original source... Go to PubMed...
    18. . Legrand M, Khanna AK, Ostermann M, Kotani Y, Ferrer R, Girardis M, et al. The renin­‑angiotensin­‑aldosterone­‑system in sepsis and its clinical modulation with exogenous angiotensin II. Crit Care. 2024;28(1):389. Go to original source... Go to PubMed...
    19. . Ostermann M, Boldt DW, Harper MD, Lim GW, Gunnerson K. Angiotensin in ECMO patients with refractory shock. Crit Care. 2018;22(1):288. Go to original source... Go to PubMed...
    20. . Levy B, Lescroart M, Combes A. Use of vasopressors and inotropes in ECMO. Intensive Care Med. 2024;50(3):463-6. Go to original source... Go to PubMed...
    21. . Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery­‑review of pathophysiology and update of treatment options. Crit Care. 2020;24(1):36. Go to original source... Go to PubMed...
    22. . Bansal M, Mehta A, Wieruszewski PM, Belford PM, Zhao DX, Khanna AK, et al. Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review. Am J Emerg Med. 2023;66:124-8. Go to original source... Go to PubMed...
    23. . Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK. Angiotensin II for Critically Ill Patients With Shock After Heart Transplant. J Cardiothorac Vasc Anesth. 2021;35(9):2756-62. Go to original source... Go to PubMed...
    24. . Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED. Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic Shock. J Cardiothorac Vasc Anesth. 2019;33(11):3080-4. Go to original source... Go to PubMed...
    25. . Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet. 1993;341(8846):703. Go to original source... Go to PubMed...
    26. . Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol. 1995;40(1):103-4. Go to original source... Go to PubMed...
    27. . Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28(10):1165-8. Go to original source... Go to PubMed...
    28. . Chen A, Wong A. The Role of Angiotensin II in Poisoning­‑Induced Shock­‑a Review. J Med Toxicol. 2022;18(2):145-54. Go to original source... Go to PubMed...
    29. . Lambden S, Creagh­‑Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018;22(1):174. Go to original source... Go to PubMed...
    30. . Ratnani I, Ochani RK, Shaikh A, Jatoi HN. Vasoplegia: A Review. Methodist Debakey Cardiovasc J. 2023;19(4):38-47. Go to original source... Go to PubMed...
    31. . Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-87. Go to original source... Go to PubMed...
    32. . Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. Jama. 2016;316(5):509-18. Go to original source... Go to PubMed...
    33. . Balik M, Novotny A, Suk D, Matousek V, Maly M, Brozek T, et al. Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction. Cardiovasc Drugs Ther. 2020;34(5):685-8. Go to original source... Go to PubMed...
    34. . Chawla LS, Busse L, Brasha­‑Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high­‑output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534. Go to original source... Go to PubMed...
    35. . Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care. 2020;24(1):227. Go to original source... Go to PubMed...
    36. . Agency EM. EU Panel Backs Angiotensin II (Giapreza) for Septic Shock 28. 6. 2019
    37. . Caragata R, Johnston SA, Chan JW, Starkey G, Bellomo R. Angiotensin­‑II and Thromboembolic Events: A Systematic Review. Crit Care Med. 2024;52(12):1894-905. Go to original source... Go to PubMed...
    38. . Legrand M, Zarbock A. Ten tips to optimize vasopressors use in the critically ill patient with hypotension. Intensive Care Med. 2022;48(6):736-9. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.